Dr. Pravin Dattatraya Badhe on LinkedIn: Network Pharmacology-Based Identification of Breast Cancer Targets and… (2024)

We were excited to participate in the #SABCS23 Poster Spotlight Session –Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and Biomarkers, by sharing our results of the #ATRACTIB clinical trial.This open-label single arm, phase II clinical trial is evaluating the combination of atezolizumab, pacl*taxel & bevacizumab for first-line advanced triple negative breast cancer.PS16-02 Efficacy and safety of first-line atezolizumab + bevacizumab + pacl*taxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.👩⚕️ PI: Dr.María Gion Cortés, Hospital Universitario Ramón y Cajal, Madrid, Spain➡️ Download the poster here:https://lnkd.in/eSJfEMPi#BreastCancer #ClinicalTrials #bringyourideatolife #ATRACTIBtrial

77

2 Comments

🎗️ On Breast Cancer Awareness Month, we are excited to share the launch of the new EORTC 2129-BCG TREAT ctDNA study on Early-Stage Breast Cancer in collaboration with MENARINI Group. The trial is expected to screen more than 1900 early-stage breast cancer patients at 120+ sites in 12 European countries, commencing in Q4 2023.The study will evaluate whether elacestrant can delay the occurrence of metastasis or death compared to standard adjuvant endocrine therapy in early-stage ER+/HER2-breast cancer patients with late ctDNA-relapse. Read the article to learn more: https://lnkd.in/eQMGZMwfMichail Ignatiadis, Emmanouil Saloustros, Wolfgang Janni#BreastCancerAwarenessMonth #PinkOCtober #TREATctDNA#CancerResearch #ClinicalTrials

40

In a recent study, researchers investigated the efficacy of sequential antibody-drug conjugate (ADC) therapy in metastatic breast cancer, specifically focusing on the use of sacituzumab govitecan (SG) and trastuzumab deruxtecan (TDXd). Modest clinical activity of both SG and TDXd when used as second-line ADC therapy (ADC2) in heavily pre-treated patients. The study highlighted that the treatment line at the time of ADC2 significantly influenced PFS, with later treatment lines correlating with shorter PFS. Moreover, the study emphasized the need for further research to explore the potential implications of payload cross-resistance, which could potentially undermine the benefits of sequential ADC therapy in metastatic breast cancer. This call for additional studies underscores the complexity of treatment strategies in advanced breast cancer and the importance of optimizing therapeutic approaches to improve patient outcomes.Read More https://lnkd.in/dzNWySZv#BreastCancerResearch #ADCTherapy #RealWorldOutcomes #PatientOutcomes #CancerTreatment

11

Small cell lung cancer (SCLC) stands as a formidable and aggressive subtype of lung cancer, notorious for its rapid growth and propensity to metastasize early. Accounting for nearly 15% of all lung cancer cases, SCLC is characterized by its quick progression, often spreading to distant organs by the time of diagnosis. This cancer type’s aggressive nature requires clinical research to identify potential treatment modalities for patients with the disease. ASTRIDE is a Phase 3 clinical trial for the treatment of extensive stage SCLC.For Additional Information:https://lnkd.in/e42_UQ6PFosun Pharma USA Inc. #lungcancer #SCLC The Balancing Act Lifetime Television#clincialtrials Payman Darouian Stan Lechpammer, MD, Ph.D. Brian Fiske George Eliades

16

Metastatic ER-positive, HER2-negative breast cancer is a type of breast cancer that has spread to other parts of the body and is characterized by the presence of estrogen receptors (ER) and the absence of human epidermal growth factor receptor 2 (HER2) receptors.Approximately 13% of women born in the US today will develop breast cancer, and of those, ~80% are estrogen receptor-positive. While there are various FDA-approved treatment options available, oncologists lack an approved biomarker to determine which treatment will be most effective for each individual patient in second-line treatment for these metastatic breast tumors. But PHASE ONE is hoping to change💡Read the full Grant Announcement for Drs. Bild and Nath at City of Hope ➡️ https://lnkd.in/gumd-2f5

14

SDBN Feed: Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA https://lnkd.in/g5zczBTY Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial expected in H2 [...]

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence.What makes CAMBRIA 1 interesting?•Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period.•Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+).Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/g-ArcYvf#BreastCancer #ClinicalTrials #ERPositiveCancer #AACR

12

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence.What makes CAMBRIA 1 interesting?•Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period.•Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+).Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/grdwv8iu#BreastCancer #ClinicalTrials #ERPositiveCancer #AACR

2

NEW: Highlights from #SABCS2023: #novelagents and insights on #HER2 dynamics in #breastcancer 🇺🇸 🎥Kevin Kalinsky, MD, MS, from the Winship Cancer Institute of Emory University, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023 💡The main focus is on new agents, including two #bispecificantibodies and a TROP-2 #antibodydrugconjugate (ADC)💡A real-world analysis, RELIEVE, underscores the importance of #HER2 dynamics, revealing potential differences in outcomes for patients with #HER2-low #primarytumors and #metastatic tumors💡The discussion emphasizes considerations about #toxicities, responses, and the optimal measurement of targets, questioning whether #targetedtherapies induce bystander effects that render assays less criticalTake a look 👉 https://lnkd.in/ethirU9d Check out our#SABCSpage for all the latest coverage 👉https://lnkd.in/eYrYkh5C#SABCS23#BreastCancer#BCsm#breastcancerawarenessAmerican Association for Cancer Research

11

🎗️ On October 13th, in observance of Metastatic Breast Cancer Awareness Day, and throughout Breast Cancer Awareness Month, Prospection stands committed to increasing awareness and enhancing treatment outcomes for all forms of breast cancer.Prospection has collaborated with eight prominent pharmaceutical customers to leverage patient-centric intelligence to bring insight into the care journey for breast cancers patients. We’ve even developed algorithms specifically for understanding the 15-20% of breast cancer occurrences that are HER2-positive, a more aggressive–but treatable–subtype.🟢 Reach out to us and discover how we can make a meaningful impact together. 👉 https://lnkd.in/gQ7jBnTS National Breast Cancer Foundation#BreastCancerAwarenessMonth #PatientCentricIntelligence #PinkOctober

32

1 Comment